In total, 452 completed clinical trials based on the use of aromatase inhibitors for breast cancer are currently registered in the database Clinical Trials, and for 163 trials results are available, including those that have led to the approval of the third generation aromatase inhibitors in current clinical practice and are briefly discussed above. This evidence concerns the gene CYP19A1 and breast cancer.